Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parental distress may undermine treatment in children with recurrent brain tumors

NCT ID NCT07660458

Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study investigates whether the emotional distress of parents—such as depression, anxiety, or trauma—affects how well children with recurrent medulloblastoma follow their treatment plans. Researchers will follow 450 parent-child pairs across four hospitals, measuring parental distress through questionnaires and tracking treatment adherence over 12 months. The goal is to identify which types of distress most strongly predict poor adherence, which could inform future support programs for families facing this devastating disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If parental distress is found to predict poor adherence, this could lead to targeted psychological support programs for caregivers, potentially improving treatment outcomes for children.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to all families, and other factors could influence adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Jun 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Parent-child dyads where child has recurrent medulloblastoma and is receiving active treatment

Ages

0 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria(Children): * Diagnosis of medulloblastoma with documented recurrence (radiographic or histopathological confirmation) * Age ≤ 18 years at enrollment * Currently receiving active treatment for recurrent disease * Life expectancy ≥ 3 months Inclusion Criteria (Parents/Caregivers): * Primary caregiver responsible for medication administration and treatment coordination * Age ≥ 18 years * Able to read and understand study materials in \[English\] * Willing to complete study assessments Exclusion Criteria: * Child receiving exclusively palliative/hospice care * Parent with severe psychiatric illness or cognitive impairment preventing informed consent or questionnaire completion * Child enrolled in another interventional trial that would confound adherence measurement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medulloblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

medulloblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medulloblastoma Recurrent medulloblastoma

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.